Please login first
Previous Article in event
Next Article in event
Test
1  Test Faculty of Health, Australian Research Centre in Complementary and Integrative Medicine, University of Technology Sydney, Ultimo, NSW 2007, Australia.
Academic Editor: Humbert G. Díaz

Abstract:

*Note: Mol2Net conference is associated to different MDPI journals special issues guest edited by Mol2Net Conference Committee members. This is an strategy to increase the online post-publication visibility of papers and conference, promote post-publication brainstorming discussion, and increase authors feedback. This association implies that our conference perform post-publication indexing of selected papers already published in MDPI journals with the consent of the issue editors. We publish free-of-cost these post-publication summaries. They include a shortened title, corresponding author info, and paper cover pdf file. The cover pdf file contains paper first page with all authors, abstract, full reference , and link to original papers.

Reference: This is a post-publication summary note for the paper published in the special issue Sustainable Materials and Technologies for Drug Delivery and Tissue Engineering, Edited by: Dr. I.A. Neacsu and Dr. B.S. Vasile, Managing Editor: C. Zha, Visit the link to see original paper. Reference: Pharmaceutics 2022, 14(11), 2384; https://doi.org/10.3390/pharmaceutics14112384
Summary: Present study deciphers development of oral polysaccharide-based colon targeted solid self-nanoemulsifying drug delivery system (S-SNEDDS) of xanthohumol (XH). Several studies have shown that XH has anti-inflammatory and antioxidant properties, suggesting that it could be a good candidate for the treatment of colorectal diseases (CRD). Despite its potential, XH has a low aqueous solubility. As a result, its bioavailability is constrained by the dissolution rate. The liquid (L)-SNEDDS was constituted using Labrafac PG as oil, Tween 80 as surfactant and Transcutol P as co-surfactant. The L-SNEDDS was then adsorbed onto the surface of guar gum and pectin and developed into S-SNEDDS powder. Ternary phase diagram was used to optimize the process of developing L-SNEDDS. The formulation showed mean droplet size of 118.96 ± 5.94 nm and zeta potential of −19.08 ± 0.95 mV and drug loading of 94.20 ± 4.71%. Dissolution studies carried out in medium containing rat caecal contents (RCC) represented the targeted release of S-SNEDDS powder. It was observed that S-SNEDDS showed less than 10% release XH in initial 5 h and rapid release occurred between the 5th and 10th hour. Results of cytotoxicity studies revealed good cytotoxicity of XH loaded S-SNEDDS for Caco2 cells as compared to raw-XH.

Pharmaceutics 2022, 14(11), 2384; https://doi.org/10.3390/pharmaceutics14112384

Keywords: Test
Comments on this paper
Shan He
Dear authors thank you for your support to the conference.
Now we closed the publication phase and launched the post-publication phase of the conference. REVIEWWWERS'08 Brainstorming Workshop is Now Open from 2023-Jan-01 to 2023-Jan-31. MOL2NET Committee, Authors, and Validated Social Media Followers Worldwide are ... Invited to Post Moderated Questions/Answers, Comments, about papers. Please kindly post your public Answers (A) to the following questions in order to promote interchange of scientific ideas. These are my Questions (Q) to you:

Q. Have you considered to testing this new coompound in clinical assays?

Dear author thanks in advance for your kind support answering the questions. Now, please become a verified REVIEWWWER of our conference by making questions to other papers in different Mol2Net congresses. Commenting Steps: Login, Go to Papers List, Select Paper, Write Comment, Click Post Comment.

Papers list: https://mol2net-08.sciforum.net/presentations/view

Workshop link: https://mol2net-08.sciforum.net/#reviewwwers



 
 
Top